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INTRODUCTION
Hepatitis B virus (HBV) infection is one of the most im-
portant chronic liver diseases worldwide, especially in sever-
al areas of Asia and Africa. More than 350 million people in
the world are persistently infected with HBV and are at risk
of developing chronic hepatitis, cirrhosis, and hepatocellular
carcinoma (HCC). Age at infection is a well-known determi-
nant of progression to chronicity (1-3). In adults with nor-
mal immunological status, less than five percent of individ-
uals with an acute hepatitis B infection go on to develop a
chronic infection, characterized by persistence of circulating
viral antigens and viral DNA. On the other hand, the rate
of evolution to the chronic state is much higher when the
infection is acquired in childhood, although the initial infec-
tion is usually clinically asymptomatic. However, the under-
lying mechanisms for the persistence of HBV or HCC occur-
rence are not fully understood.
There is growing evidence that genetic variation plays an
important role in the determination of individual suscepti-
bility to complex disease traits. It has been thought that genet-
ic associations may also provide a clue to the outcome to HBV
infection. Several lines of evidence suggest that genetic poly-
morphisms are involved in susceptibility to persistent HBV
infection or development of HCC (4-11).
Chemokines are a groups of chemotactic molecules that
specifically attract and recruit populations of immune effec-
tor cells to the sites of injury or infection (12). Their major
role is in leukocyte migration and dependent processes such
as immune surveillance and innate and adaptive immune
responses. Apart from T-cell migration, CCR5 and other
chemokine receptors mediate cell activation, costimulation,
and differentiation of T-cells and monocyte during innate
and adaptive immune response (13). The production of some
chemokines varies among individuals, and these variations
may be determined by genetic polymorphisms. 
Regulated and normal T-cell expressed and secreted (RA-
NTES) may have a role in the selective recruitment of T-cells
to portal and periportal regions in liver during inflammation
(14). It might be expected that the less frequent allele in RA-
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RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 Gene 
Polymorphisms are not Associated with the Outcome of Hepatitis B
Virus Infection: Results from a Large Scale Single Ethnic Population
Recovery from hepatitis B virus (HBV) infection depends on the cellular immune
responses. Chemokines and their receptors play significant roles in immune defense.
This study was undertaken to investigate the association between HBV infection
and single nucleotide polymorphisms (SNPs) of genes for the chemokines and their
receptors. Between March 2002 and February 2004, a total of 957 single ethnic
Korean patients were enrolled into two different groups; ‘‘HBV clearance group’’
(n=350), who have recovered from HBV infection, and ‘‘HBV persistence group’’
(n=607), who were repeatedly HBsAg-positive. The HBV persistence group was
subdivided into ‘‘inactive carrier’’ and ‘‘HBV progression group (chronic hepatitis
and cirrhosis)’’. We assessed polymorphisms in regulated and normal T-cell exp-
ressed and secreted (RANTES) at position -403, monocyte chemoattractant pro-
tein-1 (MCP-1) at position -2518, CCR2 V64I, CCR5 -2459, CXCR1 S276T and
CXCR4 I138I using single primer extension assay. Genotype distributions of the
‘‘HBV clearance versus persistence group’’ and ‘‘inactive carrier versus HBV pro-
gression group’’ were compared. On the basis of unconditional logistic regression
analysis with adjustment for age and sex, no statistically significant association
with susceptibility to persistent HBV infection was observed with RANTES -403,
MCP-1 -2518, CCR2 V64I, CCR5 -2459, CXCR1 S276T, and CXCR4 I138I poly-
morphisms. In addition, no association of analyzed SNPs with HBV disease pro-
gression was found.
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NTES gene would be associated with increased portal inflam-
mation, interface hepatitis, and severity of fibrosis. Two sin-
gle nucleotide polymorphisms (SNPs) have been described in
the RANTES promoter region, including the G-to-A sub-
stitution at position -403. There is evidence that the mutant
A allele leads to increased transcription of RANTES (15).
Monocyte chemoattractant protein-1 (MCP-1) is active on
multiple leukocyte populations showing chemotactic activi-
ty at a low concentration in vitro (16). Hepatic stellate cells
(HSCs) have been shown to regulate leukocyte trafficking
by secreting MCP-1, and it has been suggested that MCP-1
may have a direct profibrogenic action via HSC chemotaxis
(17). In vitro cells from individuals who are heterozygous or
homozygous for G at -2518 appear to produce more MCP-1
than cells from individuals homozygous for A at -2518 (18).
Hepatitis C virus (HCV) infected patients with the G allele
at position -2518 in the MCP-1 gene were reported to be more
prone to hepatic inflammation and fibrosis (19).
CCR5 was shown to act as a cofactor for entry of macro-
phage-tropic strains of HIV-1 (20). Moreover, CCR5 is a can-
didate gene for the outcome of hepatitis C virus infection. It
was reported that the frequency of the HIV-protective CCR5-
32/ 32 genotype is increased in hepatitis C (21).
CCR2 has a role in modulating the immune response as
well as recruiting monocyes/macrophages to the sites of in-
flammation has been suggested (22). One variant has been
reported in CCR2, which leads to a valine-to-isoleucine substi-
tution at amino acid position 64 (23). CCR2 V64I SNP was
reported to be associated with a delay in progression to AIDS,
and CCR2 was thought to the one of HIV-1 co-receptor (24).
CXCR1 (interleukin-8 receptor alpha) is a chemokine
receptor, which is known to have IL-8 as a binding ligand
(25). CXCR4 function as a coreceptor for T-cell line trophic
strains of HIV-1 (26).
Although chemokines and their receptors have received
increased attention, the role of chemokines and their recep-
tors in HBV infection has not been clarified. A series of stud-
ies using transgenic mouse models have demonstrated that
CD8
+ cells have the capacity to non-cytologically clear HBV
from hepatocytes that replicate HBV encoded by a transgene
(27). The protective role of HBV-specific CD8
+ cells is de-
pendent on their ability to efficiently migrate to the infected
liver, where they may exert an effector function. The migra-
tory behavior of CD8
+ cells is influenced by their expression
of different chemokines or their receptors. A recent report
showed that the ability of circulating HBV-specific CD8
+
cells of patients with low replicating virus to upregulate CCR5
suggests that these cells may respond to increases in virus rep-
lication by efficiently migrating into the infected liver (28). 
Therefore, we hypothesized that several important chemo-
kines and their receptors are deemed to be related to the out-
come of HBV infection. The purpose of this study is to ascer-
tain whether the genetic polymorphisms of RANTES, MCP-
1, CCR2, CCR5, CXCR1, and CXCR4 genes in HBV infec-
tion could influence their outcomes in terms of viral clearance
or disease progression.
MATERIALS AND METHODS
Between March 2002 and February 2004, a total of 957
patients were included in this study, and they were enrolled
from outpatient clinic of the Gastroenterology Department
and from the Center for Health Promotion of Ajou Univer-
sity Hospital, Suwon, Korea. All the patients were single eth-
nic Korean subjects. They were classified into three groups
according to the various status of HBV infection; ‘‘HBV Clear-
ance group’’ (7) [n=350, HBsAg (-), AntiHBc (+), AntiHBs
(+)], ‘‘Inactive Carrier group’’ [n=149, HBsAg (+) & HBeAg
(-), sustained normal transaminase] and ‘‘HBV progression
group (Chronic Hepatitis or Liver Cirrhosis, irrespective of
HBeAg positivity)’’ [n=458, HBsAg (+), elevated transam-
inase (≥2 times the upper limit of normal) or evidence of
cirrhosis]. Among them, inactive carrier and HBV progres-
sion groups (a total of 607 patients) were classified as the
‘‘HBV persistence’’ group who continued to be positive for
HBsAg for more than 6 months. Patients who were positive
for anti-HBs without anti-HBc, and patients with other types
of chronic liver disease were excluded from the analysis. In-
formed consent was obtained from each patient, and the Ins-
titutional Review Board of Human Research of Ajou Uni-
versity Hospital approved the study protocol.
To elucidate their role in the immunopathogenesis of HBV
infection, six polymorphisms were studied in two chemokine
(RANTES -403, MCP-1 -2518) and four chemokine recep-
tor (CCR2 V64I, CCR5 -2459, CXCR1 S276T, CXCR4
I138I) genes in Korean patients with HBV infection, and
in HBsAg negative controls who had eliminated HBV.
Genotyping
Genomic DNA was extracted from 300  L whole blood
using a DNA Purification Kit (GENTRA, Minneapolis,
MN, U.S.A.) according to the manufacturer’s instructions.
Six target polymorphisms were detected by polymerase chain
reaction (PCR) amplification. 
The sequence of the primers and probes used in the assays
are provided in Table 1. The parameters for thermocycling
were as follows: an initial activation step of 95℃ for 10 min
preceded the cycling program. All amplification conditions
were 35 cycles of 30 sec at 95℃ for denaturation, 1 min at
60℃ for annealing, followed by a single 10-min extension
cycle at 72℃. The polymorphisms were detected by single
nucleotide primer extension assay (SNP IT, Beckman Coul-
ter, Fullerton, CA, U.S.A.) using the method as previously
described (15). Briefly, the genomic DNA region spanning
the polymorphic site was PCR-amplified using one phospho-
rothiolated primer and one regular PCR primer. The amplifiedPCR products were digested with exonuclease. The 5’-phos-
phorothioates protect one strand of the PCR product from
exonuclease digestion, resulting in the generation of a single-
stranded PCR template. The single-stranded PCR template
is overlaid onto a 384-well plate that contains covalently atta-
ched SNP-IT extension primer designed to hybridize imme-
diately adjacent to the polymorphic site. The SNP-IT primer
is extended for a single base with DNA polymerase and mix-
ture of appropriate acycloterminator, which is labeled with
either fluorescein isothiocyanate (FITC) or biotin and is com-
plementary to the polymorphic nucleotide. The identity of
the incorporated nucleotide is determined with serial colori-
metric reactions with anti-FITC-alkaline phosphatase and
streptavidin-horseradish peroxidase, respectively. The results
of yellow and/or blue color developments were analyzed with
ELISA reader and the final genotype calls were made with the
QCReview program (Beckman Coulter, Fullerton, CA, U.S.A.).
Statistical analysis
Hardy-Weinberg equilibrium of alleles at individual loci
was assessed by  2-statistics. Demographic characteristics of
patients with HBV persistence or HBV clearance were com-
pared using  2-tests on categorical variables and independent
sample t-tests on normally distributed continuous variables.
Multivariate analysis was performed after adjusting for age
and sex as co-variables using SPSS version 11.0 software (SPSS,
Chicago, IL, U.S.A.). For multivariate analysis, binary logis-
tic regression analysis was performed to determine which
factor(s) was the most discriminating for HBV persistence
or the disease progression in chronic hepatitis B infection,
where age, sex, and SNPs of each gene were independent vari-
ables. Selection of variables was done by backward stepwise
deletion. All pvalues were two-tailed, and pvalue <0.05 were
considered to indicate statistical significance. 
RESULTS
Among six SNPs tested in this study, three SNPs were lo-
cated in the regulatory regions (RANTES -403, MCP-1 -2518,
CCR5 -2459) and three were in the coding regions (CCR2
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Gene SNP Primer Sequences
RANTES -403G/A PCR Forward primer TGTATATCCAGAGGACCCTCC
PCR Reverse primer TCACTGAGTCTTCAAAGTTCCTG
Genotyping primer TCCTGCTTATTCATTACAGATCTTA
MCP1 -2518A/G PCR Forward primer GGAGGGCATCTTTTCTTGA
PCR Reverse primer TTTGCATATATCAGACAGTAAACACA
Genotyping primer GAAAAGAAAGTCTTCTGGAAAGTGA
CCR5 -2459G/A PCR Forward primer GGTTGGGGTGGGATAGGG
PCR Reverse primer TTTAAATGTAGAGGGGGATCCT
Genotyping primer GATCCTGGACTTCXCATTAACCCTGTG
CCR2 V64R PCR Forward primer CTCTACTCGCTGGTGTTCATCT
PCR Reverse primer CACAATGGGAGAGTAATAAGAAAAAGC
Genotyping primer TTTGGTTTTGTGGGXAACXTGCTGGTC
CXCR1 S276T PCR Forward primer TCCTGCTGGCAGACACCC
PCR Reverse primer AAATCCCAGAATCTCAGTGG
Genotyping primer ATGAGGACCCAGGTGATCCAGGAGA
CXCR4 I138I PCR Forward primer TTTTCAGCCAACAGCTTCC
PCR Reverse primer TCCTCATCCTGGCCTTCA
Genotyping primer GCCTCTGACTGTTGGTGGCGTGGAC
Table 1. Sequences of PCR primers and genotyping primers
Chromosome band Gene name Position
Observed
heterozygotes
Expected
heterozygotes
p-value
17q11.2-q12 RANTES -403 48.40 47.10 0.421
17q11.2-q21.1 MCP-1 -2518 48.40 46.50 0.236
3p21 CCR2 V64I 39.80 39.00 1
3p21 CCR5 -2459 52.40 50.00 0.261
2q35 CXCR1 S276T 16.20 16.00 0.971
2q21 CXCR4 I138I 16.80 17.00 0.605
Table 2. Hardy-Weinberg equilibrium test
2-test was used for Hardy-Weinberg equilibrium test of alleles at individual loci.
SNP, single nucleotide polymorphism; MCP-1, monocyte chemoattractant protein-1.532 J.Y. Cheong, S.W. Cho, J.Y. Choi, et al.
V64I, CXCR1 S276T and CXCR4 I138I) of genes. In case
of CXCR1 and CXCR4 genes, one non-synonymous SNP
at codon 276 in CXCR1 coding sequences (S276T) and one
silent SNP at codon 138 in CXCR4 coding sequences (I138I)
were detected in our study population. Other sites were well-
known SNPs, which had been frequently reported.
Genotype distributions at all polymorphic sites approxi-
mated the Hardy-Weinberg equilibrium (Table 2). Allelic
variations were compared among HBV clearance and persis-
tence group and in the persistence group, inactive healthy
carrier, and the disease progression group including chronic
hepatitis and cirrhosis.
Associations between polymorphisms in chemokines
and their receptor genes and HBV clearance
Demographic characteristics of the subjects with HBV clear-
ance and persistence groups were shown in Table 3. Differ-
ences between two groups in aspartate transaminase/alanine
transaminase (AST/ALT), bilirubin, alpha-fetoprotein (AFP)
were observed. The serum levels of AST, ALT, bilirubin, and
Total (n=957) Clearance 
(n=350)
Persistence
(n=607)
p-
value
Age (mean±SD) 48.73±8.73 41.48±10.97 0.000
Sex (M:F) 253:97 445:162 0.731
AFP (ng/mL) 2.59±1.43 12.58±40.34 0.000
Platelet (×10
3/ L) 258.37±58.51 181.41±67.39 0.000
AST (U/L, mean±SD) 33.26±51.23 70.13±104.74 0.000
ALT (U/L, mean±SD) 44.07±112.85 83.31±131.47 0.000
Bilirubin (mg/dL, mean±SD) 1.03±1.88 1.36±2.25 0.027
Albumin (g/dL, mean±SD) 4.39±0.32 4.15±1.10 0.000
Table 3. Demographic characteristics in ‘‘HBV clearance’’ vs.
‘‘HBV persistence’’ subjects
2-test was used for categorical variables and independent sample t-
test for normally distributed continuous variables.
AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
SNP locus Genotype Clearance 
(n=350)
Persistence
(n=607)
p-
value
RANTES -403 AA 44 (12.6%) 84 (13.8%) 0.766
GA 178 (50.9%) 296 (48.8%)
GG 128 (36.6%) 227 (37.4%)
MCP-1 -2518 AA 42 (12%) 78 (12.9%) 0.724
GA 164 (46.9%) 299 (49.3%)
GG 144 (41.1%) 230 (37.9%)
CCR2 -V64I AA 26 (7.4%) 39 (6.4%) 0.819
GA 138 (39.4%) 234 (38.6%)
GG 186 (53.1%) 334 (55.0%)
CCR5 -2459 AA 91 (26.0%) 144 (23.7%) 0.842
GA 176 (50.3%) 322 (53.0%)
GG 83 (23.7%) 141 (23.2%)
CXCR1 -S276T CC 2 (0.6%) 5 (0.8%) 0.841
GC 56 (16.0%) 103 (17.0%)
GG 292 (83.4%) 499 (82.2%)
CXCR4 -I138I AA 5 (1.4%) 5 (0.8%) 0.782
GA 59 (16.9%) 99 (16.3%)
GG 286 (81.7%) 503 (82.9%)
Table 4. Logistic regression analysis of polymorphisms with the
HBV clearance whilst controlling for age and sex as covariates
For multivariate analysis, binary logistic regression analysis was performed
after adjusting for age and sex as co-variables. Selection of variables
was done by backward stepwise deletion.
SNP, single nucleotide polymorphisms; MCP-1, monocyte chemoat-
tractant protein-1.
Total (n=607) Inactive carrier
(n=149)
Progression
(n=458)
p
Age (mean±SD) 41.50±11.04 41.48±10.95 0.986
Sex (M:F) 94:55 351:107 0.001
AFP (ng/mL) 3.80±7.90 15.70±46.38 0.065
Platelet (×10
3/ L) 218.74±64.24 170.58±64.43 0.000
AST (U/L, mean±SD) 28.21±8.06 83.59±117.19 0.000
ALT (U/L, mean±SD) 30.93±12.62 100.25±147.16 0.000
Bilirubin (mg/dL, mean±SD) 1.11±2.37 1.43±2.21 0.168
Albumin (g/dL, mean±SD) 4.36±0.43 4.09±1.22 0.019
Table 5. Demographic characteristics in ‘‘Inactive HBV carriers’’
vs. ‘‘HBV progression’’ subjects
2-test was used for categorical variables and independent sample t-
test for normally distributed continuous variables.
AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
SNP locus Genotype Inactive Carrier
(n=149 )
Progression* 
(n=458 )
p-
value
RANTES -403 AA 20 (13.4%) 64 (14.0%) 0.869
GA 74 (49.7%) 222 (48.5%)
GG 55 (36.9%) 172 (37.6%)
MCP-1 -2518 AA 22 (14.8%) 56 (12.2%) 0.833
GA 71 (47.7%) 228 (49.8%)
GG 56 (37.6%) 174 (38.0%)
CCR2 -V64I AA 14 (9.4%) 25 (5.5%) 0.127
GA 60 (40.3%) 174 (38.0%)
GG 75 (50.3%) 259 (56.6%)
CCR5 -2459 AA 36 (24.2%) 108 (23.6%) 0.515
GA 77 (51.7%) 245 (53.5%)
GG 36 (24.2%) 105 (22.9%)
CXCR1 -S276T CC 1 (0.7%) 4 (0.9%) 0.573
GC 21 (14.1%) 82 (17.9%)
GG 127 (85.2%) 372 (81.2%)
CXCR4 -I138I AA (0.0%) 5 (1.1%) 0.841
GA 23 (15.4%) 76 (16.6%)
GG0 126  (84.6%) 377  (82.3%)
Table 6. Logistic regression analysis of polymorphisms with the
HBV clearance whilst controlling for age and sex as covariates
*Chronic hepatitis or liver cirrhosis.
For multivariate analysis, binary logistic regression analysis was per-
formed after adjusting for age and sex as co-variables. Selection of vari-
ables was done by backward stepwise deletion.
SNP, single nucleotide polymorphisms; MCP-1, monocyte chemoat-
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AFP at baseline were significantly higher in the HBV per-
sistence group. No significant differences were detected bet-
ween the clearance group and the persistence group in the
distribution of gender, but the age tended to be younger in
the persistence group.
All SNP frequencies were analyzed for an association with
spontaneous clearance versus HBV persistence. Genotype dis-
tributions and p-value for logistic analysis whilst controlling
for age and sex as covariates are shown (Table 4). In multivari-
ate analysis after adjustment for age and sex, there was no
significant difference in the frequencies of allele in the ana-
lyzed genes between the HBV clearance group and the HBV
persistence group (Table 4).
Associations between polymorphisms in chemokines and
their receptor genes and HBV disease progression
For the further analysis of the relationship between chemo-
kine/chemokine receptor gene SNPs and disease progression
in HBV infection, the persistence group was divided into
non-progressive group (inactive carrier) and the progression
group (chronic hepatitis and liver cirrhosis).
Demographic characteristics of the subjects with ‘‘inactive
carrier’’ vs. ‘‘HBV progression’’ group are summarized in
Table 5. No significant differences were identified between
two groups in the distributions of their age, but male gender
was predominant in the disease progression group. AST, ALT,
albumin, platelets were different between the two groups. The
serum levels of AST, ALT at baseline were significantly higher
in HBV progression group.
Table 6 demonstrates the allele frequencies of polymorphic
loci investigated between the inactive carrier and HBV pro-
gression groups. No statistically significant relationship was
seen between genetic polymorphisms in chemokines and their
receptor genes and the HBV disease progression. 
DISCUSSION
This is a large case-control study, looking at six SNPs in a
group of chemokines and their receptors in single ethnic pop-
ulation. Six polymorphisms in chemokine-related genes were
analyzed in 607 Korean HBV carriers and 350 who had eli-
minated HBV as a control. The allelic frequencies of inves-
tigated genes in ‘‘HBV clearance group’’ did not differ from
the frequencies in ‘‘HBV persistence group’’. No significant
differences in the distribution of genotypes associated with
chemokines and their receptor gene polymorphisms could
be demonstrated between ‘‘Inactive carrier group’’ and ‘’HBV
progressive group’’ in this study.
In Korea, vertical transmission of HBV in infancy is a major
cause of chronic infection. The age at which an individual is
infected determines the likelihood of the development of
chronic infection. Thus, ethnic differences in the mode of
infection and the distribution of allelic polymorphisms may
account for the lack of the correlation in our study. Common
methodologic limitations of genetic epidemiologic studies
include a low sample size leading to a lack of statistical power.
In the present study, we analyzed a large number of cases (n=
957) of a single ethnic origin, therefore our results may raise
the statistical power of this study.
During the last few years, numerous association studies
have investigated the role of genetic polymorphisms in the
outcome of HBV infection (4-9). We also have shown that
the interleukin-10 and tumor necrosis factor- promoter
SNPs influenced the HBV clearance after acute infection (11).
Chemokines and their receptors have received increasing atten-
tion in the last few years. It is now clear that chemokines
participate in many pathological conditions like inflamma-
tion and are likely key regulators of immune responses (25).
However, there are few reports about association between che-
mokine related gene SNPs and the outcome of HBV infection.
This study has some limitations. The natural course of chro-
nic hepatitis B can be divided into several phases based on
virus-host interaction; immune tolerance phase, immune clear-
ance phase, inactive carrier or chronic hepatitis, eventually
cirrhosis, and/or hepatocelluar carcinoma. In this study, the
family history of HBV infection could not be completely eval-
uated, and it was hard to presume the onset of HBV infec-
tion. Moreover, inactive carrier and progression groups could
not be exactly divided because most enrolled subjects did not
undergo liver biopsy. Even though we tried to compensate
the confounding effects by adjusting age and sex, limitations
from a cross-sectional study could not be neglected. Unfor-
tunately, we could not categorize the patient population by
virological status (HBeAg and HBV-DNA) due to incom-
plete data.
CCR5 is a strong candidate gene for the outcome of HCV
infection.(21) But their roles in HBV infection are not clear.
In a recent investigation, Chang et al. have shown that CCR5
promoter SNPs might influence the HBV clearance in Kore-
an population (29), whereas our study did not find any such
correlation in the same ethnic Korean population. Discrepant
results may result from demographic factors and differences
in the study design.
Recently, MCP-1 gene SNP was reported to be associated
with hepatic MCP-1 expression and the severity of HCV-
related liver disease (19). Although there is no evidence of a
role for MCP-1 in the pathogenesis of HBV in the literature,
it is a potential candidate gene because it could affect the sus-
ceptibility to persistent HBV infection, inflammatory res-
ponse, or liver fibrosis. The results from this study showed
no significant association with susceptibility to persistent
HBV carriage. Such discrepancy may reflect differences in
the immunopathogenesis of HBV and HCV infection.
Although none of the SNPs studied are likely to have major
effects on the outcome of HBV infection, we should consid-
er that chemokine expression may be disease stage-specific,and serum levels may not necessarily correlate with hepatic
expression. Determination of the exact functional consequences
of these polymorphisms need more detailed and careful in
vitro as well as in vivo studies.
In conclusion, this study has attempted to elucidate the
role of genetic polymorphisms in chemokines and their recep-
tors in the outcome of HBV infection, but showed no asso-
ciation between HBV clearance or disease progression in HBV
infection and chemokines or chemokine receptors gene poly-
morphisms. Further studies are needed to determine  whether
an association exists between the outcome of HBV infection
including antiviral treatment response of chronic hepatitis B
and genetic polymorphisms in other chemokines.
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